Efficacy
A MaHR was achieved by 22 (55%) and 19 (43%) of patients in the once and twice-daily groups, respectively. MCyR was seen in 28 (70%) and 23 (52%) patients, without significant difference between the two groups.r
The median PFS was 4.0 months in the once-daily group and 3.1 months in the twice-daily group (p=0.735). The median OS was 6.5 months in the once-daily group and 9.1 months in the twice-daily group (p=0.336). There were no significant differences in outcomes between either once or twice-daily dosing. Only 2 patients in the once-daily group and 3 patients in the twice-daily group were still on therapy at 2-year follow-up, though 5 patients discontinued in order to proceed to transplant.r
There did not appear to be a difference in outcome between those patients who failed imatinib due to resistance and those who experienced imatinib intolerance. The three patients with T315I mutation detected had no objective response to dasatinib, as would be expected.r
Dasatinib is optimally combined with chemotherapy for efficacy in Philadelphia positive ALL.rr
Figure 1: Kaplan-Meier analysesr
C: Progression-free survival computed on all randomised patients. Patients who neither progressed nor died were censored on the date of last cytogenetic or haematologic assessment.
D: Overall survival computed on all randomised patients. Patients who had not died or who were lost to follow-up were censored on the last date on which they were known to have been alive.
CI, confidence interval; NA, not available.
© American Journal of Hematology 2010